Webinar: Non-Viral Manufacturing of Gene Modified CAR-T Therapies Using TcBuster™

Dr. David Hermanson, Director for Cell and Gene Therapy Applications at Bio-Techne, presents a technical talk focusing on how gene modified cell therapies can be manufactured at scale using the TcBuster™ transposon system, specialty media, and liquid cytokines. Dr. Hermanson’s talk also describes how automated Simple Plex™ assays on Ella™ can be used for the functional assessment of CAR-T cells.

Topics Covered

• Learn how gene modified cell therapies can be manufactured at scale using the TcBuster transposon system, specialty media, and liquid cytokines
• Discover how untouched CAR-T cells can be expanded utilizing the G-Rex^® 100M bioreactor
• Utilization of Simple Plex assays for CAR-T cell functional assessment on Ella, an automated ELISA platform

Speaker

David Hermanson, PhD

Director, Cell and Gene Therapy Applications, Bio-Techne

David has greater than 10 years experience in using non-viral gene editing for the production of CAR-T and CAR NK cells. He is currently the Director of C&GT Applications at Bio-Techne providing workflow solutions utilizing non-viral gene editing capabilities, specialty medias, and GMP proteins. Prior to joining Bio-Techne, he worked at BMoGen Biotechnologies advancing the TcBuster transposon system, now owned by Bio-Techne. David has also worked extensively with the piggyBac™ transposon system while at Poseida Therapeutics first as an R&D scientist and then as a process development scientist and manager for their CAR-T clinical candidates. He received his PhD from the University of Minnesota in medicinal chemistry before doing a post-doctoral fellowship using non-viral gene editing in iPSCs and CAR design for NK cells.